Singular Genomics Shares Outstanding vs. Price To Earning
| OMIC Stock | USD 21.25 0.20 0.93% |
For Singular Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Singular Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Singular Genomics Systems utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Singular Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Singular Genomics Systems over time as well as its relative position and ranking within its peers.
Singular |
Singular Genomics' Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share 1.107 | Quarterly Revenue Growth 0.459 | Return On Assets (0.24) | Return On Equity (0.52) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Singular Genomics Systems Price To Earning vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Singular Genomics's current stock value. Our valuation model uses many indicators to compare Singular Genomics value to that of its competitors to determine the firm's financial worth. Singular Genomics Systems is rated below average in shares outstanding category among its peers. It is regarded third in price to earning category among its peers . The ratio of Shares Outstanding to Price To Earning for Singular Genomics Systems is about 70,338 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Singular Genomics' earnings, one of the primary drivers of an investment's value.Singular Price To Earning vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Singular Genomics |
| = | 2.51 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Singular Genomics |
| = | 35.71 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Singular Price To Earning Comparison
Singular Genomics is currently under evaluation in price to earning category among its peers.
Singular Genomics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Singular Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Singular Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Singular Genomics' change in net profit over the period of time. It can combine multiple indicators of Singular Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 155 K | 162.8 K | |
| Net Interest Income | 7.4 M | 7.7 M | |
| Interest Income | 8.4 M | 8.9 M | |
| Operating Income | -102.8 M | -97.7 M | |
| Net Loss | -92.7 M | -88 M | |
| Income Before Tax | -94.8 M | -99.6 M | |
| Total Other Income Expense Net | 8 M | 8.4 M | |
| Net Loss | -81.8 M | -85.9 M | |
| Net Loss | -94.8 M | -99.6 M | |
| Income Tax Expense | 9.1 M | 9.5 M | |
| Non Operating Income Net Other | 3 M | 3.1 M | |
| Change To Netincome | 15.8 M | 16.6 M | |
| Net Loss | (39.08) | (41.03) | |
| Income Quality | 0.78 | 0.89 | |
| Net Income Per E B T | 1.12 | 1.10 |
Singular Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Singular Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Singular Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Singular Genomics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Singular Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Use Investing Themes to Complement your Singular Genomics position
In addition to having Singular Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Books Thematic Idea Now
Books
Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
To fully project Singular Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Singular Genomics Systems at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Singular Genomics' income statement, its balance sheet, and the statement of cash flows.